Biognosys Announces Strategic Agreement with Siemens Healthineers
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it has established a strategic agreement with Siemens Healthineers, a global medical technology company, through its clinical laboratory in Berkeley, California. The agreement leverages Biognosys’ expertise in unbiased biomarker discovery technologies and solutions with Siemens Healthineers’ biomarker assay development, lab testing, and commercialization capabilities.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “With this agreement we can enable our biopharmaceutical customers to use the power of our proprietary discovery proteomics solution for novel biomarker identification and bring these biomarkers into clinical applications with Siemens Healthineers’ diagnostic assay development expertise.”
Using Biognosys’ proprietary Hyper Reaction Monitoring (HRMTM) mass spectrometry technology, thousands of proteins may be quantified simultaneously from a broad range of clinical sample types. HRM enables an unmatched depth of proteome coverage with reproducible and precise quantification to identify the most promising, actionable biomarkers to support clinical decision making. This discovery proteomics solution can be applied with high throughput in large-scale studies involving thousands of samples.
The strategic agreement enables discovery of novel biomarkers via the HRM technology followed by translation into validated biomarker assays for potential clinical applications. This may include clinical trials usage and In Vitro Diagnostics development programs.
Sebastian Kronmueller, Head of Siemens Healthcare Laboratory in California, commented: “We are excited about this relationship with Biognosys because their expertise and unique biomarker discovery capabilities are very complementary to our end-to-end diagnostic solutions for our biopharmaceutical customers.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company’s proprietary solutions provide a multi-dimensional view of protein expression, function, and structure in all major biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading, precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005039/en/
Contact information
Media Contact Biognosys
Oliver Rinner, PhD
Chief Executive Officer
Phone +41 (0) 44 738 20 40
oliver.rinner@biognosys.com
Media Contact Siemens Healthineers
Lance Longwell, MBA
Director Of Communications And Public Relations
Phone +1 (610) 883-0788
lance.longwell@siemens-healthineers.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Momentum Recognized as a Clutch Global Honoree and Champion for Fall 20259.12.2025 18:09:00 EET | Press release
HTEC Momentum (formerly Momentum Design Lab), HTEC’s research, product design, management and innovation arm, has earned two of Clutch’s highest distinctions—Global Award honoree and Clutch Champion—reaffirming its ninth straight year as the platform’s top-rated UX agency worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209358771/en/ HTEC Momentum Recognized as a Clutch Global Honoree and Champion for Fall 2025 The Clutch Global Awards honorees are selected based on demonstrated industry expertise and exceptional delivery—evaluated through thousands of verified client reviews published on Clutch. Clutch’s rigorous, case-study-driven review process includes extensive verification to ensure the authenticity and depth of each submission. These distinctions further underscore HTEC Momentum’s position as a top-rated leader in UX strategy, design, and user research, reflecting the consistent satisfaction of our clients
Onego Bio Launches “ The Power of Trichoderma reesei ” Series to Showcase Innovation, Scale, and Real-World Applications9.12.2025 18:00:00 EET | Press release
Onego Bio, a food ingredient company producing non-animal egg protein with precision fermentation*, today announced the launch of a new expert series titled “The Power of Trichoderma reesei: Building the Future with Fungi.” This multi-part initiative reveals the full potential of Trichoderma reesei, the microbial platform behind Onego’s Bioalbumen®, by spotlighting its scientific strengths, industrial scale, and practical performance across food manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209632524/en/ Headshot of Dr. Sharief Barends The first session, “Why Trichoderma reesei is Precision Fermentation’s Quiet Workhorse,” will be held on December 18, 2025, featuring Dr. Sharief Barends, Head of Research Leiden (Netherlands) and Head of Fungal Genetics at IFF, and Dr. Christopher Landowski, Co-Founder and Chief Technology Officer at Onego Bio. Together, they will explore the research legacy, strengths, and
Guinea Emerges as West Africa's New Digital Transformation Powerhouse9.12.2025 17:53:00 EET | Press release
The Republic of Guinea has reached a decisive turning point as a regional digital power. By hosting the Transform Africa Summit 2025, becoming the first francophone nation to receive this major continental event since its creation in 2013, Guinea confirmed the emergence of Conakry as a new digital innovation hub in West Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209780892/en/ Rose Pola Pricemou, Minister of Posts, Telecommunications and Digital Economy of the Republic of Guinea (Photo: AETOSWire) The numbers break all records: over 7,000 participants from 79 countries, including 47 ministers, 1,552 government representatives, 584 business leaders, over 590 start-ups, and 14 MoUs signed. Never before in the history of the Transform Africa Summit has such mobilisation been accomplished. This unprecedented turnout demonstrates international confidence in Guinea's ability to lead Africa's digital transformation ch
Rapid Medical™ Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13™ for Distal Vessel Occlusions9.12.2025 17:47:00 EET | Press release
Rapid Medical™, a leading developer of active endovascular devices, announces the completion of patient enrollment in the DISTALS Trial, a multicenter randomized study assessing the TIGERTRIEVER 13™ device in patients with distal medium vessel occlusions (DMVO) in acute ischemic stroke. “DMVO strokes represent up to 40% of ischemic strokes and can cause significant disability, yet their treatment has remained uncertain. Recent neutral results from ESCAPE-MEVO and DISTAL made one thing clear: distal thrombectomy requires devices and trials specifically engineered for distal vessels,” said Dr. Jeffrey Saver of UCLA in California, Principal Investigator of DISTALS. “TIGER 13 and DISTALS bring that dedicated design. Completing enrollment is a major step toward evidence that can truly advance care for these patients.” The TIGER 13 is purpose-built for distal interventions. Its proprietary adjustable design is the only thrombectomy device that can actively remove tension from the vessel duri
Suzano Launches Nature Strategy and Reinforces the Strategic Importance of Biodiversity Conservation to the Business9.12.2025 17:41:00 EET | Press release
Suzano, the world’s largest pulp producer, has launched its Nature Strategy, reaffirming the company's commitment to biodiversity and how it guides decision-making within the business. Suzano's operations depend directly on nature, and the company recognizes that its longevity and ability to innovate are intrinsically linked to the health of ecosystems. Therefore, nature occupies a significant strategic role in the business’ vision. The science-led Nature Strategy, developed in collaboration with IUCN, is guided by the mitigation hierarchy: avoid, reduce, restore and transform. This approach enables the prevention of impacts, the minimization of risks, and the promotion of ecosystem regeneration. With support from IUCN, Suzano has pioneered the use of the STAR metric – a tool that enables the company to map sensitive areas within the territories where it operates, identify endangered species, and set priority actions required to reduce their risk of extinction. Biodiversity monitoring
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom